#United States #New York #Faruqi & Faruqi #Sarepta Therapeutics #ELEVIDYS

Legal Investigation of Sarepta Therapeutics by Faruqi & Faruqi

In a significant move for investors impacted by Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Faruqi & Faruqi, LLP, a renowned national securities law firm, is launching an investigation into potential claims. This investigation comes in light of recent events that have raised serious concerns regarding the company's conduct, particularly regarding the ELEVIDYS gene therapy treatment.

Background on the Investigation

Faruqi & Faruqi has issued a reminder to investors that the deadline for taking action is August 25, 2025. This marks the date by which claimants can seek to assume the role of lead plaintiff in a federal securities class action lawsuit against Sarepta. Investors who suffered losses exceeding $100,000 from the company's depreciating stock value between June 22, 2023, and June 24, 2025, are encouraged to reach out to attorney Josh Wilson for an overview of their options.

The primary allegations suggest that Sarepta and its executives may have breached federal securities laws by making misleading statements and failing to disclose crucial safety risks associated with ELEVIDYS. This treatment is currently under scrutiny due to reports of severe adverse events, including patient fatalities.

Timeline of Events

The unfolding drama began with Sarepta’s safety update on March 18, 2025, when the company disclosed the death of a patient following the treatment. This revelation led to a sharp decline of approximately 27% in stock prices, underscoring investor fears and erasing significant market capital. Following the adverse report, on April 4, 2025, European regulatory authorities requested additional reviews, prompting Sarepta to halt patient recruitment in certain trials. This further exacerbated the situation as the stock plummeted again by over 7%.

As if this wasn't troubling enough, on June 15, 2025, another patient’s death due to acute liver failure was reported, which led Sarepta to suspend shipments aimed at non-ambulatory patients. The announcement of these events contributed to a staggering reduction of over 42% in stock value, ultimately closing at $20.91 per share. To compound investors' woes, on June 24, 2025, the FDA issued a Safety Communication acknowledging the investigation into potential risks associated with ELEVIDYS, which resulted in yet another decline of 8% in share price.

Implications for Investors

The sequence of events has understandably raised alarm bells among shareholders. With the allegations of misleading information regarding the safety and efficacy of their product, many investors who relied on management's assurances find themselves financially vulnerable. The essence of this legal investigation is to determine the culpability of Sarepta's executives in potentially misleading investors and whether there is a basis for compensation for those affected.

How to Participate

Faruqi & Faruqi emphasizes the importance of a collective effort from investors to navigate this situation. Each potential lead plaintiff will play a crucial role in overseeing the litigation on behalf of the larger investor community. If you believe you could be affected and wish to have a say in the proceedings, you can either put forth your desire to serve as lead plaintiff or choose to remain an unnamed class member, which should not affect your entitlement to any recovery should the class action prove successful.

For additional information, investors with pertinent insights about Sarepta's practices are urged to contact Faruqi & Faruqi, including former employees and whistleblowers. The law firm has made its intent clear: they're dedicated to ensuring that all investors are appropriately heard and represented.

Conclusion

As the deadline approaches for taking legal action, affected investors are advised to act promptly to safeguard their rights. The investigation led by Faruqi & Faruqi, LLP, not only sheds light on the serious allegations against Sarepta but also represents a crucial step toward accountability that could potentially lead to significant recoveries for those adversely affected by their investment decisions.